DIVISLAB's weekly return of 3.4% outperformed its peers, with a Sharpe Ratio of 0.56 indicating a moderate risk-adjusted return. The stock's volatility of 24.17% was higher than its peers, suggesting a riskier investment. Compared to its peers, DIVISLAB underperformed CIPLA but outperformed DRREDDY and SUNPHARMA. Overall, the stock's performance was decent, but its high volatility warrants caution.

[Volatility: 24.17%]